As of Monday, CymaBay Therapeutics Inc.’s (NASDAQ:CBAY) stock closed at $8.31, up from $7.80 the previous day. While CymaBay Therapeutics Inc. has overperformed by 6.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CBAY rose by 200.00%, with highs and lows ranging from $8.40 to $1.67, whereas the simple moving average jumped by 132.72% in the last 200 days.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
On April 11, 2022, Cantor Fitzgerald started tracking CymaBay Therapeutics Inc. (NASDAQ: CBAY) recommending Overweight. A report published by H.C. Wainwright on August 04, 2020, Reiterated its previous ‘Buy’ rating for CBAY. Piper Sandler also rated CBAY shares as ‘Overweight’, setting a target price of $12 on the company’s shares in an initiating report dated July 31, 2020. SVB Leerink May 12, 2020d its ‘Mkt Perform’ rating to ‘Outperform’ for CBAY, as published in its report on May 12, 2020. Stifel’s report from May 12, 2020 suggests a price prediction of $8 for CBAY shares, giving the stock a ‘Buy’ rating. ROTH Capital also rated the stock as ‘Buy’.
Analysis of CymaBay Therapeutics Inc. (CBAY)
One of the most important indicators of CymaBay Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -110.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 12.20, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CBAY is recording 959.25K average volume. On a monthly basis, the volatility of the stock is set at 7.61%, whereas on a weekly basis, it is put at 8.49%, with a gain of 25.72% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.44, showing growth from the present price of $8.31, which can serve as yet another indication of whether CBAY is worth investing in or should be passed over.
How Do You Analyze CymaBay Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
At the end of the first quarter, Nantahala Capital Management LLC decreased its CBAY holdings by -6.42% and now holds 2.47 million CBAY shares valued at $15.52 million with the lessened -0.17 million shares during the period. CBAY shares are owned by institutional investors to the tune of 76.30% at present.
